Cellular Biomedicine Group Inc. , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, announced today that Dr. William Cao, Chief Executive Officer of the Company will discuss the Company's Phase IIb interim clinical data on its Rejoin TM human adipose-derived mesenchymal progenitor cell therapy for Knee Osteoarthritis and its CAR-T cell therapy for cancer clinical development programs at the 2015 Annual Regen Med Investor Day to be held on Wednesday, March 25, 2015 at 11:20 AM EDT at the Metropolitan Club in New York City. A live-streaming webcast of all panels and company presentations will be available at: http://ift.tt/1FC3M7R .
http://ift.tt/191tAxl
http://ift.tt/191tAxl
No comments:
Post a Comment